A quicker-than-expected U.S. approval
of Regeneron Pharmaceuticals high-dose eye disease
drug, Eylea, should help return the blockbuster treatment back
to growth in the next few years, Wall Street.
Regeneron pulled off a rare double play on Friday afternoon as it scored two FDA approvals one under the radar and the other highly anticipated. | With the…